contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    pageUrl
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
  ... on Webcast {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
      researchContent {
        title
        lang
        pdfUrl
        relatedContent {
          __typename
          ...PublishingDetails
          ...Reactions
          id
        }
        content {
          title
          lang
          slug
          htmlBody
          publishedAt
          createdAt
          changedAt
          isOutdated
          isPremium
        }
      }
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


aiforia-technologies-strong-cross-read-from-roches-pathai-takeover-nuways-ag-research-r

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

LinkedIn              Development of convolutional neural networks for automated brain-wide...    Speeding up image analysis time from weeks to minutes. ⏱️ That's how AI is transforming preclinical synucleinopathy research.   Traditional characterization of histological samples in neurodegenerative disease research is labor-intensive and...                             Nye forskningsresultater fra Aiforia vedrørende forskning i musehjerner, formentlig relateret til undersøgelse af neurologiske sygdomme som Parkinsons sygdom. Jeg må læse det igennem, når jeg får tid.

Er der nogen information om, hvad prisen på handlen er?

Grundium, en virksomhed med rødder i Herwantas kamera- og computersynsklynge, har opkøbt Aiforias konkurrent Visiopharm. Det ser ud til, at virksomheder, der leverer disse maskinlæringsmodeller og software, er i høj kurs i øjeblikket.                   Grundium – 21 May 26              Grundium Acquires Visiopharm to Create Integrated Precision Pathology Platform    Grundium has completed the acquisition of Visiopharm, a global leader in AI-driven precision pathology software.         Est. reading time: 4 minutes

Denne var her ikke endnu, @Antti_Siltanen interviewer administrerende direktør Jukka Tapaninen: Aiforian kuulumiset: Foundation Enginellä nopeutta ja skaalautuvuutta tuotekehitykseen - Inderes

Her roser Dr. Zuraw Aiforia i et afsnit, der starter omkring 12:30 minutter inde i videoen. Det drejer sig om hjælp til den pakistanske patolog Zehra Talat, som Aiforia reagerede på, da andre ikke gjorde. Dette er god reklame for Aiforia.

Jeg gad vide, om der kommer en meddelelse om en ny rettet emission i næste uge. Sidste år fandt emissionen sted den 27. maj, og året før var det den 22. maj. Ved emissionen for to år siden fik de rejst ca. 10 millioner, og ved emissionen i maj sidste år blev det til ca. 8 millioner. Sidste år fik de vist færre penge ind end forventet, da de besluttede at gennemføre endnu en emission den 10. december, som indbragte ca. 4,2 millioner til kassen. Derudover afholdt de fyringsrunder (muutosneuvottelut) i slutningen af året, som de vurderer vil give årlige omkostningsbesparelser på ca. 2,5 millioner. Hvis man estimerer, at de stadig har brug for ca. 10 millioner årligt, så ville der allerede være 4,7 millioner til rådighed for i år (8 + 4,2 + 2,5 - 10). Så mon det er nok for i år, hvis de indsamler lidt over 5 millioner i “kollekt”?

De økonomiske nøgletal for unoterede selskaber er på et meget usikkert grundlag, så vurderingen af værdiansættelsesniveauer kan nemt ramme helt ved siden af. Et par kommentarer: Ifølge visse kilder (GrowJo, Zoominfo) skulle PathAI’s omsætning have været ~100 MUSD. Disse tal bør nok tages med et gran salt. Det ville betyde en P/S-multipel på groft sagt 10x baseret på historiske tal og den fulde købspris. Tempus AI betalte 81 MUSD for Paige, hovedsageligt med egne aktier. Der var investeret 220 MUSD i Paige. AZ - Modella AI. Købspris ikke oplyst. Evident - Pramana. Købspris ikke oplyst. Leica - Indica, investering, detaljer ikke oplyst.

Aiforia Technologies

(Link updated) Last week, Roche announced the acquisition of PathAI for up to $ 1.05bn ($ 750m upfront, $ 300m in earnouts), to be integrated into its Diagnostics division. PathAI is privately...

(Link updated)<br><br>Last week, Roche announced the acquisition of PathAI for up to $ 1.05bn ($ 750m upfront, $ 300m in earnouts), to be integrated into its Diagnostics division. PathAI is privately held, and few valuation details are provided in connection with the deal. PathAI divested its lab services business to Quest Diagnostics for $ 100m in June 2024. Post-divestment, this could put PathAI's FY25 sales at a range of $ 30-40m, implying a deal valuation of 26-35x sales (incl. earnouts). At Friday close, Aiforia traded at 18.3x EV/S FY25 and 12.4x EV/S FY26 (eNuW).<br><br>Large healthtech companies are betting big on AI. In this context, Aiforia stands out as the leading AI play in clinical oncology diagnostics. We make no changes to our DCF model, and reiterate our BUY rating with a € 3.80 PT.

Aiforia Technologies: Strong cross-read from Roche's PathAI takeover - NuWays AG Research (R)

Aiforia Technologies: Strong cross-read from Roche's PathAI takeover - NuWays AG Research (R)